Teva Pharmaceutical Industries (TEVA) Invested Capital (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Invested Capital across 18 years of filings, most recently posting $10.8 billion for Q1 2026.

• Quarterly Invested Capital rose 62.03% year-over-year to $10.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.8 billion (up 62.03% YoY) and the FY2025 annual result came in at $9.7 billion, up 35.93% from the prior year.
• Invested Capital rose to $10.8 billion in Q1 2026, from $9.7 billion in the prior quarter.
• Over five years, Invested Capital peaked at $12.3 billion in Q1 2022 and troughed at $6.7 billion in Q1 2025.
• A 5-year average of $9.5 billion and a median of $9.6 billion in 2023 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2025 — Invested Capital sank 36.9% — and 2026, when it jumped 62.03%.
• Tracing TEVA's Invested Capital over 5 years: stood at $10.7 billion in 2022, then dropped by 8.49% to $9.8 billion in 2023, then retreated by 26.91% to $7.2 billion in 2024, then jumped by 35.93% to $9.7 billion in 2025, then climbed by 11.36% to $10.8 billion in 2026.
• Business Quant data shows TEVA's Invested Capital at $10.8 billion in Q1 2026, $9.7 billion in Q4 2025, and $7.3 billion in Q3 2025.